DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical 0.4% Ketorolac and Vitreoretinal Surgery

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Surgery

Intervention: Ketorolac (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Stephen J Kim, MD, Principal Investigator, Affiliation: Emory University

Summary

To determine whether use of topical 0. 4% ketorolac has any effect on pupil size during vitreoretinal surgery.

Clinical Details

Official title: Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-controlled, Double-masked Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome: Change in pupil size during vitreoretinal surgery

Secondary outcome: Postoperative pain and inflammation

Detailed description: Other outcomes will be to assess postoperative pain and inflammation and visual acuity.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age of 18, routine elective vitrectomy

Exclusion Criteria:

- history of trauma, uveitis, prior intraocular surgery within 3 months, requirement of

mechanical pupil dilation, prior inclusion of other eye

Locations and Contacts

Emory Eye Clinic, Atlanta, Georgia 30322, United States
Additional Information

Starting date: November 2006
Last updated: May 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017